HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock.
TransCode Therapeutics Stock Down 9.6 %
Shares of TransCode Therapeutics stock opened at $0.59 on Thursday. TransCode Therapeutics has a twelve month low of $0.22 and a twelve month high of $19.42. The company has a fifty day moving average price of $0.44 and a 200 day moving average price of $0.70.
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.16). Equities research analysts expect that TransCode Therapeutics will post -2.06 earnings per share for the current fiscal year.
Institutional Trading of TransCode Therapeutics
TransCode Therapeutics Company Profile
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Recommended Stories
- Five stocks we like better than TransCode Therapeutics
- Stock Dividend Cuts Happen Are You Ready?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Stock Splits, Do They Really Impact Investors?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Overbought Stocks Explained: Should You Trade Them?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.